Rubraca and Sluggishness - a phase IV clinical study of FDA data

Summary:

Sluggishness is reported as a side effect among people who take Rubraca (rucaparib camsylate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Zofran, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Sluggishness when taking Rubraca. It is created by eHealthMe based on reports of 10,770 people who have side effects when taking Rubraca from the FDA, and is updated regularly.

What is Rubraca?

Rubraca has active ingredients of rucaparib camsylate. eHealthMe is studying from 10,770 Rubraca users. Check the latest studies of Rubraca.

What is Sluggishness?

Sluggishness (lacking alertness) is found to be associated with 783 drugs and 748 conditions by eHealthMe. Check the latest studies of Sluggishness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

10,770 people reported to have side effects when taking Rubraca.
Among them, 18 people (0.17%) have Sluggishness.

Among these 18 people:

How long have people been on Rubraca when they have Sluggishness? *

What is the gender of people who have Sluggishness when taking Rubraca? *

female: 100 %
male: 0.0 %

What is the age of people who have Sluggishness when taking Rubraca? *

What are other drugs people take besides Rubraca? *

What are other side effects people have besides Sluggishness? *

Fatigue (feeling of tiredness): 13 people, 72.22%
Nausea (feeling of having an urge to vomit): 13 people, 72.22%
Itching: 7 people, 38.89%
Abdominal Discomfort: 6 people, 33.33%
Taste - Impaired: 6 people, 33.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 33.33%
Indigestion: 5 people, 27.78%
Dry Skin: 5 people, 27.78%
Nausea And Vomiting: 5 people, 27.78%
Dehydration (dryness resulting from the removal of water): 4 people, 22.22%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 16 people, 88.89%
Fallopian Tube Cancer (cancer of fallopian tube): 3 people, 16.67%
Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 2 people, 11.11%
Ill-Defined Disorder: 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Rubraca and have Sluggishness?

- Check whether Sluggishness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rubraca:

Rubraca (10,770 reports)

Sluggishness treatments and more:

Sluggishness (11,737 reports)

Browse all side effects of Rubraca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sluggishness:

Sluggishness (783 drugs)

Browse all the conditions that are associated with Sluggishness:

Sluggishness (748 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rucaparib camsylate (the active ingredients of Rubraca) and Rubraca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.